# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Piper Sandler analyst Matt O'Brien reiterates DexCom (NASDAQ:DXCM) with a Overweight and maintains $90 price target.
DexCom's Stelo Glucose Biosensor System, the first over-the-counter continuous glucose monitor, is now available without a ...
Available for purchase today at Stelo.com for people in the U.S. 18 and older not using insulinProvides 24/7 powerful and perso...
Stifel analyst Mathew Blackman maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price target from $90 to $100.
S&P 500 ended Tuesday's session with slight declines, halting its best winning streak since May 2024. Here's the la...
S&P 500 and Nasdaq 100 indices gain for seventh straight day, marking best weekly performance since October 2023 on positiv...